Oncomatryx Biopharma has been awarded €12.5 million in EIC Accelerator funding to advance groundbreaking ADCs for oncology. This funding includes €2.5 million in grants and €10 million in equity investment.

Jul 15, 2025•5 months ago

Amount Raised

€12.5 Million

Autonomous Community Of The Basque CountryTherapeuticsBiotechnologyHealth Care

Description

Oncomatryx Biopharma, a biotechnology company specializing in Antibody-Drug Conjugates (ADCs) for oncology, received €12.5 million in EIC Accelerator funding. This funding, part of the EU's Horizon Europe program, includes €2.5 million in grants and €10 million in equity investment. A total of 40 companies were selected from 959 applications. This funding will help advance their Phase I clinical trial for difficult-to-treat cancers.

Company Information

Company

Oncomatryx Biopharma

Location

Autonomous Community Of The Basque Country, Spain

About

Oncomatryx Biopharma is a biotechnology company pioneering next-generation Antibody-Drug Conjugates (ADCs) for oncology. The company's unique ADC platform integrates proprietary novel payloads and advanced conjugation formats, supporting innovative drug development. With a focus on treating hard-to-treat solid tumors, Oncomatryx is recognized as a strategic leader in oncology innovation. The company is advancing its lead ADC candidate, OMTX705, targeting aggressive tumors with high unmet medical needs.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Oncomatryx Biopharma has been awarded €12.5 million in EIC Accelerator funding to advance groundbreaking ADCs for oncology. This funding includes €2.5 million in grants and €10 million in equity investment.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information